ArticleEuropean journal of nuclear medicine and molecular imaging2022
Matched-pair analysis of [
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06972628 (177Lu-PSMA-617), which is not on this map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
177Lu-PSMA-617 (Pluvicto) for the Treatment of Patients With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Super Scan Bone Scan
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Dosimetry of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Pooled it
- Overall Survival with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC): results of phase Ia study.European journal of nuclear medicine and molecular imaging · 2026Article
- Single-cell and spatial multi-omics reveal mechanistic insights of FOLH1+ endothelial cells in clear cell renal cell carcinoma.Journal of translational medicine · 2026Article
- Longitudinal renal function following [¹⁷⁷Lu]Lu-PSMA I&T in metastatic castration-resistant prostate cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- Could we reduce renal toxicity of [European journal of nuclear medicine and molecular imaging · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2026Article
- Lesion-level quantitative Lu-177 PSMA SPECT/CT SUV metrics are associated with interim treatment response in mCRPC: a PET-correlated study.Annals of nuclear medicine · 2026Article
- Development and evaluation of improved in-house procedure for radiolabelling of theranostic agent [EJNMMI radiopharmacy and chemistry · 2026Article
- Post-Therapeutic Dosimetry of Metastatic Castration-Resistant Prostate Cancer WithAsia-Pacific journal of clinical oncology · 2026Article
- Prognostic value of whole-body tumor SUV dispersion on baseline PSMA PET prior to PSMA radioligand therapy.Annals of nuclear medicine · 2026Article
- Real-world outcomes of 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: the KuPSMALu trial in Eastern Finland.Acta oncologica (Stockholm, Sweden) · 2025Observational
- AI-driven body composition monitoring and its prognostic role in mCRPC undergoing lutetium-177 PSMA radioligand therapy: insights from a retrospective single-center analysis.EJNMMI research · 2025Article
- Innovative Peptide Therapeutics in the Pipeline: Transforming Cancer Detection and Treatment.International journal of molecular sciences · 2025Review
- Use ofWiener klinische Wochenschrift · 2025Article
- Radiotheranostic landscape: A review of clinical and preclinical development.European journal of nuclear medicine and molecular imaging · 2025Review
- First real-world clinical experience with [European journal of nuclear medicine and molecular imaging · 2025Article
- Experience of rescue therapy with [European journal of nuclear medicine and molecular imaging · 2025Article
- An overview of current phase 3 radiopharmaceutical therapy clinical trials.Frontiers in medicine · 2025Review
- Advances in PSMA-Targeted Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.Cancer management and research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLabelled with lutetium-177, the urea-based small molecules PSMA I&T and PSMA-617 are the two agents most frequently used for radioligand therapy (RLT) in patients with advanced metastatic castration-resistant and prostate-specific membrane antigen (PSMA) expressing prostate cancer (mCRPC). In this matched-pair analysis, we aimed to compare the toxicity and efficacy of both agents for PSMA-directed RLT. MATERIALS AND
methodsA total of 110 mCRPC patients from two centres were accrued, 55 individuals treated with [
resultsToxicity assessment revealed grade III anaemia in a single patient (1.8%) for [
conclusionIn this matched-pair analysis of patients receiving one of the two agents most frequently applied for PSMA RLT, the rate of clinically relevant toxicities was low for both compounds. In addition, no relevant differences for OS were observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.